February 25, 2019 07:47 AM EST
R&D

As­traZeneca's clot-fight­er Bril­in­ta shows promise in di­a­bet­ics with heart dis­ease in big study

Natalie Grover

Reporter

As Pas­cal So­ri­ot pol­ish­es the rough edges of his R&D shop with­in As­traZeneca, the British drug­mak­er re­port­ed some en­cour­ag­ing news that could help it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

New Trump era could be a boon for bio­phar­ma M&A, deal­mak­ing

GSK CEO Em­ma Walm­s­ley on the new Trump ad­min­is­tra­tion, trust, AI and Chi­na

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Cal­i­for­nia vot­ers say yes to re­stric­tions around 340B spend­ing

‘We’re good’ on weight loss: Bio­phar­mas turn to mus­cle with new obe­si­ty drugs

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times